Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305676 · ClinicalTrials.gov registry record
Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
A clinical trial of Oropharyngeal Cancer and HPV-Related Carcinoma, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Recruiting
- Registry status
- 400
- Enrollment target
- 2
- Study locations
NCT06305676 is a study of Oropharyngeal Cancer and HPV-Related Carcinoma that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 400 participants, above the 174-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (130% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT06305676, a study of Oropharyngeal Cancer and HPV-Related Carcinoma, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 2
- Study locations
Study Summary
Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, age, race/ethnicity, and tobacco use collected from the Moffitt Cancer Center (Moffitt) and the University of Pittsburgh Medical Center Hillman Cancer Center (Pittsburgh).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST combined HPV 16 DNA and host gene methylation oral biomarker panel
Study Locations (2)
Florida
- Moffitt Cancer Center - Tampa
Pennsylvania
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-01-22 |
| Est. Completion | 2029-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305676
The ClinicalTrials.gov registry entry for NCT06305676 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 174-participant average among 25 other Oropharyngeal Cancer trials with a reported enrollment target (130% higher). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Oropharyngeal Cancer appearing as the primary indexed condition, and to 1 intervention - of which combined HPV 16 DNA and host gene methylation oral biomarker panel is the first listed.
NCT06305676 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06305676 about?
NCT06305676 is a clinical study titled "Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)". Investigators seek to determine the sensitivity and specificity of a combined HPV 16 DNA and host gene methylation oral biomarker panel to distinguish early Oropharyngeal Cancer (OPC) cases from controls among 100 early and 100 late disease pre-treatment OPC cases, and 200 controls matched by sex, a...
What is the current status of trial NCT06305676?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2024-01-22. Estimated completion is 2029-01.
What conditions does trial NCT06305676 study?
This clinical trial studies the following conditions: Oropharyngeal Cancer, HPV-Related Carcinoma.
What interventions are being tested in trial NCT06305676?
The interventions under investigation include: combined HPV 16 DNA and host gene methylation oral biomarker panel (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06305676?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305676 being conducted?
This trial has 2 study locations across Florida, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Oropharyngeal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
RECRUITING · Phase 2
-
BALSTILIMAB on Viral Clearance in HPV+ Oropharyngeal Cancer Patients
RECRUITING · Phase 2
-
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
RECRUITING · Phase 2
-
Liposomal Bupivacaine and Transoral Robotic Surgery
RECRUITING
-
SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer
RECRUITING · Phase 3
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.